Stimulant and Atypical Antipsychotic Medications For Children Placed in Foster Homes

PLoS ONE

Volumn 8, Issue 1, 2013, Pages

  Linares, L Oriana ^a   Martinez Martin, Nuria ^b   Castellanos, F Xavier ^b,c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c NATHAN S KLINE INSTITUTE FOR PSYCHIATRIC RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; CENTRAL STIMULANT AGENT; MOOD STABILIZER; NEUROLEPTIC AGENT;

ADOLESCENT; AGE DISTRIBUTION; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CHILD ABUSE; COHORT ANALYSIS; COMORBIDITY; DISEASE ASSOCIATION; DRUG EFFICACY; DRUG MONITORING; DRUG SAFETY; DYSTHYMIA; ETHNIC GROUP; FEMALE; FOSTER CARE; GENERALIZED ANXIETY DISORDER; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; MEDICAL HISTORY; MEDICAL PRACTICE; MENTAL DISEASE; OPPOSITIONAL DEFIANT DISORDER; OUTCOME ASSESSMENT; POSTTRAUMATIC STRESS DISORDER; PRESCHOOL CHILD; PRESCRIPTION; PROSPECTIVE STUDY; SCHOOL CHILD; SEPARATION ANXIETY; SEX DIFFERENCE; SEXUAL DYSFUNCTION; UNITED STATES;

ADOLESCENT; AFRICAN AMERICANS; ANTIPSYCHOTIC AGENTS; ANXIETY, SEPARATION; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; COMORBIDITY; FEMALE; FOSTER HOME CARE; HISPANIC AMERICANS; HUMANS; MALE; PROSPECTIVE STUDIES;

EID: 84872179442     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0054152     Document Type: Article

References (56)

1. US Department of Health and Human Services: The Children's Bureau (2010) Child welfare outcomes 2007-2010: Report to Congress. http://www.acf.hhs.gov/programs/cb/pubs/cwo07-10/cwo07-10.pdf. Accessed September 2012.
2. Linares LO, Li MM, Shrout PE, Ramirez-Gaite M, Hope S, (2010) The course of inattention and hyperactivity/impulsivity symptoms after foster placement. Pediatrics 125: e489-e498.
3. Hurlburt MS, Leslie LK, Landsverk J, Barth RP, Burns BJ, et al. (2004) Contextual predictors of mental health service use among children open to child welfare. Arch Gen Psychiatry 6: 1217-1224.
4. Schneiderman JU, (2003) Health issues of children in foster care. Contemp Nurse 14: 123-128.
5. Staudt MM, (2003) Mental health services utilization by maltreated children: Research findings and recommendations. Child Maltreat 8: 195-203.
6. US Department of Health and Human Services: Administration for Children and Families' Office of Planning, Research and Evaluation (2005) National survey of child and adolescent well-being (NSCAW). http://www.acf.hhs.gov/sites/default/files/opre/cps_report_revised_090105.pdf. Accessed September 2012.
7. Arizona Department of Health Services (2006) Psychotropic medication in children, adolescents and youth adults. http://www.azdhs.gov/bhs/guidance/psychotropic.pdf. Accessed September 2012.
8. Health and Human Services Commission (2006) Use of psychoactive medication in Texas foster children state fiscal year 2005. http://www.hhs.state.tx.us/news/release/Analysis_062306.pdf. Accessed September 2012.
9. Texas Department of State Health Services (2007) Psychotropic medication utilization parameters for foster children 2005. http://www.dshs.state.tx.us/mhprograms/pdf/PsychotropicMedicationUtilizationParametersFosterChildren.pdf. Accessed September 2012.
10. McMillen JC, Zima BT, Scott LD Jr, Auslander WF, Munson MR, et al. (2005) Prevalence of psychiatric disorders among older youths in the foster care system. J Am Acad Child Adolesc Psychiatry 44: 88-95.
11. Tremmery S, Buitelaar JK, Steyaert J, Molenberghs G, Feron FJ, et al. (2007) The use of health care services and psychotropic medication in a community sample of 9-year-old schoolchildren with ADHD. Eur Child Adolesc Psychiatry 16: 327-336.
12. Raghavan R, Zima BT, Andersen RM, Leibowitz AA, Schuster MA, et al. (2005) Psychotropic medication use in a national probability sample of children in the child welfare system. J Child Adolesc Psychopharmacol 15: 97-106.
13. Leslie LK, Raghavan R, Hurley M, Zhang J, Landsverk J, et al. (2011) Investigating geographic variation in use of psychotropic medications among youth in child welfare. Child Abuse and Neglect 35: 333-342.
14. Rubin D, Matone M, Huang YS, dosReis S, Feudtner C, et al. (2012) Interstate variation in trends of psychotropic medication use among Medicaid-enrolled children in foster care. Children and Youth Services Review 34: 1492-1499.
15. Zito JM, Safer DJ, Sai D, (2008) Psychotropic medication patterns among youth in foster care. Pediatrics 121: e157-e163.
16. Correll CU, (2008a) Antipsychotic use in children and adolescents: minimizing adverse effects to maximize outcomes. J Am Acad Child Adolesc Psychiatry 47: 9-20.
17. Correll CU, (2008b) Monitoring and management of antipsychotic-related metabolic and endocrine adverse events in pediatric patients. Int Rev Psychiatry 20: 195-201.
18. Shin L, Bregman H, Frazier J, Noyes N, (2008) An overview of obesity in children with psychiatric disorders taking atypical antipsychotics. Harv Rev Psychiatry 16: 69-79.
19. Leslie LK, Gordon JN, Lambros K, Premji K, Peoples J, et al. (2005) Addressing the developmental and mental health needs of young children in foster care. J Dev Behav Pediatr 26: 140-15.
20. Silver J, Dicker S, (2007) Mental health assessment of infants in foster care. Child Welfare 86: 35-55.
21. Linares LO, (2006) An understudied form of intra-family violence: Sibling-to-sibling aggression among foster children. Aggression and Violent Behavior 11: 95-109.
22. Linares LO, Li M, Shrout PE, Brody GH, Pettit GS, (2007) Placement shift, sibling relationship quality, and child outcomes in foster care: a controlled study. J Fam Psychol 21: 736-743.
23. Bartnett D, Manly JT, Cicchetti D, (1991) Continuing toward an operational definition of psychological treatment. Dev Psychopathol 3: 19-29.
24. National Institute of Mental Health (2002) Medications. http://www.nimh.nih.gov/publicat/index.cfm. Accessed May 2012.
25. Physician's Desk Reference (2007) http://www.pdr.net/psychiatry/.Accessed May 2012.
26. Bravo M, Ribera J, Rubio-Stipec M, Canino G, Shrout P, et al. (2001) Test-retest reliability of the Spanish version of the Diagnostic Interview Schedule for Children (DISC-IV). J Abnorm Child Psychol 29: 433-444.
27. Shaffer D, Fisher P, Lucas CP, Dulcan MK, Schwab-Stone ME, (2000) NIMH Diagnostic Interview Schedule for Children Version IV (NIMH DISC-IV): description, differences from previous versions, and reliability of some common diagnoses. J Am Acad Child Adolesc Psychiatry 39: 28-38.
28. Piacentini J, Roper M, Jensen P, (1999) Informant-based determinants of symptom attenuation in structured child psychiatric interviews. J Abnorm Child Psychol 27: 417-428.
29. Piacentini JC, Cohen P, Cohen J, (1992) Combining discrepant diagnostic information from multiple sources: Are complex algorithms better than simple ones? J Abnorm Child Psychol 20: 51-63.
30. Eyberg S, Pincus D (1999) Eyberg Child Behavior Inventory and Sutter-Eyberg Student Behavior Inventory. Odessa, FL: Psychological Assessment Resources.
31. Hardin JW & Hilbe JM (2003) Generalized Estimating Equations. Boca Raton, FL: Chapman and Hall.
32. Garland AF, Hough RL, McCabe KM, Yeh M, Wood PA, et al. (2001) Prevalence of psychiatric disorders in youths across five sectors of care. J Am Acad Child Adolesc Psychiatry 40: 409-418.
33. Tarren-Sweeney M, (2008) The mental health of children in out-of-home care. Curr Opin Psychiatry 21: 345-349.
34. Aparasu RR, Bhatara V, (2005) Antipsychotic prescribing trends among youths, 1997-2002. Psychiatr Serv 56: 904-9015.
35. Aparasu RR, Bhatara V, (2007) Patterns and determinants of antipsychotic prescribing in children and adolescents, 2003-2004. Curr Med Res Opin 23: 49-56.
36. Comer JS, Olfson M, Mojtabai M, (2010) National trends in child and adolescent psychotropic polypharmacy in office-based practice, 1996-2007. J Am Acad Child Adolesc Psychiatry 49: 1001-1010.
37. Safer D, Zito JM, dosReis S, (2003) Concomitant psychotropic medication for youths. American Journal of Psychiatry 160(3): 438-449.
38. Findling RL, (2008) Atypical antipsychotic treatment of disruptive behavior disorders in children and adolescents. J Clin Psychiatry 69: 9-18.
39. Ipser J, Stein DJ, (2006) Systematic review of pharmacotherapy of disruptive behavior disorders in children and adolescents. Psychopharmacology 191: 127-140.
40. Jensen PS, Kettle L, Roper MT, Sloan MT, Dulcan MK, et al. (1999) Are stimulants overprescribed? Treatment of ADHD in four U.S. communities. J Am Acad Child Adolesc Psychiatry 38: 797-804.
41. Froehlich TE, Lanphear BP, Epstein JN, Barbaresi WJ, Katusic SK, et al. (2007) Prevalence, recognition, and treatment of attention-deficit/hyperactivity disorder in a national sample of US children. Arch Pediatr Adolesc Med 161: 857-864.
42. Reich W, Huang H, Todd RD, (2006) ADHD medication use in a population-based sample of twins. J Am Acad Child Adolesc Psychiatry 45: 801-807.
43. Angold A, Erkanli A, Egger HL, Costello EJ, (2000) Stimulant treatment for children: a community perspective. J Am Acad Child Adolesc Psychiatry 39: 975-984.
44. Armenteros JL, Lewis JE, Davalos M, (2007) Risperidone augmentation for treatment-resistant aggression in attention-deficit/hyperactivity disorder: a placebo-controlled pilot study. J Am Acad Child Adolesc Psychiatry 46: 558-565.
45. Ruths S, Steiner H, (2004) Psychopharmacologic treatment of aggression in children and adolescents. Pediatr Ann 33: 318-327.
46. Staller JA, (2007) Psychopharmacologic treatment of aggressive preschoolers: a chart review. Prog Neuropsychopharmacol Biol Psychiatry 31: 131-135.
47. Swann AC, (2003) Neuroreceptor mechanisms of aggression and its treatment. J Clin Psychiatry 64Suppl 4: 26-35.
48. Correll CU, Carlson HE, (2006) Endocrine and metabolic adverse effects of psychotropic medications in children and adolescents. J Am Acad Child Adolesc Psychiatry 45: 771-791.
49. Leslie LK, Weckerly J, Landsverk J, Hough RL, Hurlburt MS, et al. (2003) Racial/ethnic differences in the use of psychotropic medication in high-risk children and adolescents. J Am Acad Child Adolesc Psychiatry 42: 1433-1442.
50. Zito JM, Safer DJ, Riddle MA, Johnson RE, Speedie SM, et al. (1998) Prevalence variations in psychotropic treatment of children. J Child Adolesc Psychopharmacol 8: 99-105.
51. Boles M, Lynch FL, DeBar LL, (2001) Variations in pharmacotherapy for attention deficit hyperactivity disorder in managed care. J Child Adolesc Psychopharmacol 11: 43-52.
52. Bellows NM, Halpin HA, (2008) Impact of Medicaid reimbursement on mental health quality indicators. Health Serv Res 43: 582-597.
53. dosReis S, Owens PL, Puccia KB, Leaf PJ, (2004) Multimodal treatment for ADHD among youths in three Medicaid subgroups: disabled, foster care, and low income. Psychiatr Serv 55: 1041-1048.
54. Landon BE, Rosenthal MB, Normand SL, Frank RG, Epstein AM, (2008) Quality monitoring and management in commercial health plans. Am J Manage Care 14: 377-386.
55. Landon BE, Schneider EC, Normand SL, Scholle SH, Pawlson LG, et al. (2007) Quality of care in Medicaid managed care and commercial health plans. JAMA 298: 1674-1681.
56. Tang MH, Hill KS, Boudreau AA, Yucel RM, Perrin JM, et al. (2008) Medicaid managed care and the unmet need for mental health care among children with special health care needs. Health Serv Res 43: 882-900.